Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...

Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, ...

Repatha will be available through AmgenNow for $239 per month, which is nearly 60% less than its current list price in the U.S. The company said that the new price for Repatha is the lowest among the ...

Amgen Inc. (NASDAQ:AMGN) is one of the Best Wide Moat Stocks to Buy Right Now. The company possesses a wide economic moat, ...

Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...

J&J reports today, just two weeks after Pfizer secured certainty on tariffs and drug pricing. Analysts expect to hear about ...

Amgen introduces AmgenNow, a direct-to-patient program for Repatha, offering affordable access to life-saving cardiovascular ...

Amgen makes Repatha available through AmgenNow, a direct-to-patient programme in the US: Thousand Oaks, California Wednesday, October 8, 2025, 17:00 Hrs [IST] Amgen announced the ...

The company has initiated this DTC program with its blockbuster cholesterol-lowering drug Repatha, which will be available at a monthly price of $239 — a nearly 60% discount to its U.S. list price.

In today's Pharmalittle roundup, we're reading about Novo Nordisk layoffs, an Amgen discount program, and more.

A mgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the current ...